JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

First published online June 15, 2007
J Nucl Med 2007, doi:10.2967/jnumed.106.035915
 © 2007 by Society of Nuclear Medicine
This Article
Right arrow Full Text (Publish Ahead of Print[PDF])
Right arrow All Versions of this Article:
jnumed.106.035915v1
48/7/1077    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hadi, M.
Right arrow Articles by Carrasquillo, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hadi, M.
Right arrow Articles by Carrasquillo, J. A.

Brown Fat Imaging with 18F-6-Fluorodopamine PET/CT, 18F-FDG PET/CT, and 123I-MIBG SPECT: A Study of Patients Being Evaluated for Pheochromocytoma

Mohiuddin Hadi 1, Clara C. Chen 1, Millie Whatley 1, Karel Pacak 2, and Jorge A. Carrasquillo 1*

1 Department of Nuclear Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland
2 Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland

* To whom correspondence should be addressed. E-mail: carrasj1{at}mskcc.org.


  Abstract

Several radiopharmaceuticals such as 18F-FDG, 123I-metaiodobenzylguanidine (MIBG), and 99mTc-tetrofosmin have demonstrated uptake in brown adipose tissue (BAT). It is important to recognize these normal variants so that they are not misinterpreted as a significant pathologic state. In addition, these radiopharmaceuticals may shed light on BAT physiology. 18F-6-fluorodopamine (F-DA) is being used as a PET radiopharmaceutical to image adrenergic innervation and suspected pheochromocytoma. Past reports have suggested that BAT is increased in pheochromocytoma patients. Methods: The images of 96 patients evaluated with 18F-F-DA or 18F-FDG PET/CT for known or suspected pheochromocytoma were reviewed retrospectively to determine whether localized uptake of a pattern typically associated with BAT was present. When available, contemporaneous images obtained using 123I-MIBG were also reviewed for the presence of BAT. Results: Of 67 patients imaged with 18F-F-DA, BAT was found in 17.9%. Of 83 patients imaged with 18F-FDG, 19.2% had BAT. Discordant findings related to uptake in BAT were often seen in patients studied with 18F-FDG, 18F-F-DA, or 123I-MIBG. Overall, 26 (27.0%) of 96 patients showed BAT on at least 1 of the 3 imaging modalities. Conclusion: 18F-F-DA can image BAT, most likely by localizing to sympathetic innervations in a manner similar to 123I-MIBG. Patients with pheochromocytoma may have a greater BAT tissue mass or activation because of elevated levels of circulating catecholamines. Quantitative PET with 18F-FDG and 18F-F-DA may have a role in in vivo studies of BAT physiology in humans or animal models.

Key Words: PET, PET/CT, brown fat, 18F-FDG, 123I-MIBG, 18F-fluorodopamine






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.